CASP3 and neoplasm: Higher caspase-3 activity inhibition by B18R supplementation was seen in A549 and U87MG tumor cells (52.6% and 31.3%, respectively) rather than in NB1RGB and HEK293 normal cells (9.2% and −6.1%, respectively) as seen in Fig. 2b, although the significant difference in Caspase-3 activity between NDV and NDV-inhibitor groups was only observed in A549 cells (Fig. 2a).